Active 0 6 0 6 B-chronic_disease
and 7 10 7 10 I-chronic_disease
uncontrolled 11 23 11 23 I-chronic_disease
infections 24 34 24 34 I-chronic_disease
will 35 39 35 39 O
cause 40 45 40 45 O
patients 46 54 46 54 O
to 55 57 55 57 O
be 58 60 58 60 O
excluded 61 69 61 69 O

All 0 3 70 73 O
allograft 4 13 74 83 O
patients 14 22 84 92 O
> 23 24 93 94 O
2 25 26 95 96 B-lower_bound
years 27 32 97 102 I-lower_bound
of 33 35 103 105 O
age 36 39 106 109 B-age

Children 0 8 110 118 O
less 9 13 119 123 O
than 14 18 124 128 O
2 19 20 129 130 B-upper_bound
years 21 26 131 136 I-upper_bound
of 27 29 137 139 O
age 30 33 140 143 B-age
will 34 38 144 148 O
be 39 41 149 151 O
excluded 42 50 152 160 O
due 51 54 161 164 O
to 55 57 165 167 O
increased 58 67 168 177 O
hepatotoxicity 68 82 178 192 B-chronic_disease
from 83 87 193 197 O
valproic 88 96 198 206 B-treatment
acid 97 101 207 211 I-treatment
in 102 104 212 214 O
this 105 109 215 219 O
age 110 113 220 223 O
group 114 119 224 229 O

Karnofsky 0 9 230 239 B-clinical_variable
score 10 15 240 245 I-clinical_variable
greater 16 23 246 253 O
than 24 28 254 258 O
or 29 31 259 261 O
equal 32 37 262 267 O
to 38 40 268 270 O
70 41 43 271 273 B-lower_bound
% 43 44 273 274 I-lower_bound
or 45 47 275 277 O
Performance 48 59 278 289 B-clinical_variable
status 60 66 290 296 I-clinical_variable
of 67 69 297 299 O
< 70 71 300 301 O
or 72 74 302 304 O
= 75 76 305 306 O
2 77 78 307 308 B-upper_bound
by 79 81 309 311 O
the 82 85 312 315 O
Eastern 86 93 316 323 B-clinical_variable
Cooperative 94 105 324 335 I-clinical_variable
Oncology 106 114 336 344 I-clinical_variable
Group 115 120 345 350 I-clinical_variable
( 121 122 351 352 I-clinical_variable
ECOG 122 126 352 356 I-clinical_variable
) 126 127 356 357 I-clinical_variable
scale 128 133 358 363 I-clinical_variable

Low 0 3 364 367 O
risk 4 8 368 372 O
AML 9 12 373 376 B-cancer
in 13 15 377 379 O
complete 16 24 380 388 O
remission 25 34 389 398 O
1 35 36 399 400 O
, 36 37 400 401 O
will 38 42 402 406 O
not 43 46 407 410 O
be 47 49 411 413 O
candidates 50 60 414 424 O
for 61 64 425 428 O
this 65 69 429 433 O
study 70 75 434 439 O

Patients 0 8 440 448 O
already 9 16 449 456 O
receiving 17 26 457 466 O
valproic 27 35 467 475 B-treatment
acid 36 40 476 480 I-treatment
or 41 43 481 483 O
receiving 44 53 484 493 O
other 54 59 494 499 O
anticonvulsants 60 75 500 515 B-treatment
will 76 80 516 520 O
be 81 83 521 523 O
excluded 84 92 524 532 O

Patients 0 8 533 541 O
must 9 13 542 546 O
have 14 18 547 551 O
undergone 19 28 552 561 O
allogeneic 29 39 562 572 B-treatment
stem 40 44 573 577 I-treatment
cell 45 49 578 582 I-treatment
transplant 50 60 583 593 I-treatment
within 61 67 594 600 O
40 68 70 601 603 B-lower_bound
- 70 71 603 604 O
60 71 73 604 606 B-upper_bound
days 74 78 607 611 I-upper_bound
before 79 85 612 618 O
starting 86 94 619 627 O
treatment 95 104 628 637 B-treatment
and 105 108 638 641 O
be 109 111 642 644 O
self 112 116 645 649 O
- 116 117 649 650 O
sufficient 117 127 650 660 O
in 128 130 661 663 O
caloric 131 138 664 671 O
intake 139 145 672 678 O
along 146 151 679 684 O
with 152 156 685 689 O
no 157 159 690 692 O
active 160 166 693 699 O
graft 167 172 700 705 B-chronic_disease
vs. 173 176 706 709 I-chronic_disease
host 177 181 710 714 I-chronic_disease
disease 182 189 715 722 I-chronic_disease

Patients 0 8 723 731 O
with 9 13 732 736 O
an 14 16 737 739 O
absolute 17 25 740 748 B-clinical_variable
neutrophil 26 36 749 759 I-clinical_variable
count 37 42 760 765 I-clinical_variable
less 43 47 766 770 O
than 48 52 771 775 O
1500 53 57 776 780 B-upper_bound
will 58 62 781 785 O
be 63 65 786 788 O
excluded 66 74 789 797 O

Patients 0 8 798 806 O
with 9 13 807 811 O
platelets 14 23 812 821 B-clinical_variable
less 24 28 822 826 O
than 29 33 827 831 O
50,000 34 40 832 838 B-upper_bound
will 41 45 839 843 O
be 46 48 844 846 O
excluded 49 57 847 855 O

Patients 0 8 856 864 O
with 9 13 865 869 O
refractory 14 24 870 880 O
or 25 27 881 883 O
relapsed 28 36 884 892 O
: 36 37 892 893 O
acute 38 43 894 899 B-cancer
myelogenous 44 55 900 911 I-cancer
leukemia 56 64 912 920 I-cancer
( 65 66 921 922 I-cancer
AML 66 69 922 925 I-cancer
) 69 70 925 926 I-cancer
( 71 72 927 928 O
including 72 81 928 937 O
inv16 82 87 938 943 O
, 87 88 943 944 O
t(8;21 89 95 945 951 O
) 95 96 951 952 O
or 97 99 953 955 O
t(15;17 100 107 956 963 O
) 107 108 963 964 O
) 108 109 964 965 O
or 110 112 966 968 O
high 113 117 969 973 B-cancer
risk 118 122 974 978 I-cancer
myelodysplastic 123 138 979 994 I-cancer
syndrome 139 147 995 1003 I-cancer
( 148 149 1004 1005 I-cancer
MDS 149 152 1005 1008 I-cancer
) 152 153 1008 1009 I-cancer

bilirubin 0 9 1010 1019 B-clinical_variable
of 10 12 1020 1022 O
< 13 14 1023 1024 O
2mg 15 18 1025 1028 B-upper_bound
/ 18 19 1028 1029 I-upper_bound
dL 19 21 1029 1031 I-upper_bound
, 21 22 1031 1032 O
serum 23 28 1033 1038 B-clinical_variable
glutamate 29 38 1039 1048 I-clinical_variable
pyruvate 39 47 1049 1057 I-clinical_variable
transaminase 48 60 1058 1070 I-clinical_variable
< 61 62 1071 1072 O
3 63 64 1073 1074 B-upper_bound
* 65 66 1075 1076 I-upper_bound
ULN 67 70 1077 1080 I-upper_bound

creatinine 0 10 1081 1091 B-clinical_variable
< 11 12 1092 1093 O
2mg 13 16 1094 1097 B-upper_bound
/ 16 17 1097 1098 I-upper_bound
dL 17 19 1098 1100 I-upper_bound

defined 0 7 1101 1108 O
as 8 10 1109 1111 O
bone 11 15 1112 1116 B-clinical_variable
marrow 16 22 1117 1123 I-clinical_variable
blasts 23 29 1124 1130 I-clinical_variable
> 30 31 1131 1132 O
or 32 34 1133 1135 O
= 35 36 1136 1137 O
5 37 38 1138 1139 B-lower_bound
% 38 39 1139 1140 I-lower_bound

pregnant 0 8 1141 1149 B-pregnancy
females 9 16 1150 1157 B-gender
are 17 20 1158 1161 O
excluded 21 29 1162 1170 O

